ライフサイエンスコーパス: amebiasis

1 inal inflammation in persons with intestinal amebiasis.

2 al parasite, is the causative agent of human amebiasis.

3 lity of children in the Bangladesh cohort to amebiasis.

4 of apoptosis in a mouse model of intestinal amebiasis.

5 E. histolytica, the protozoan cause of human amebiasis.

6 n and colonization in a mouse cecal model of amebiasis.

7 amoeba histolytica in human and experimental amebiasis.

8 standing the role of host immune response in amebiasis.

9 pen our understanding of the pathogenesis of amebiasis.

10 istolytica, the species that causes clinical amebiasis.

11 re protective and not damaging in intestinal amebiasis.

12 with any of the clinical outcomes related to amebiasis.

13 contribution of the host immune response in amebiasis.

14 ritical insights into immunity to intestinal amebiasis.

15 et for therapy and/or prevention of invasive amebiasis.

16 we know little about protective immunity to amebiasis.

17 tant are less virulent in an animal model of amebiasis.

18 idate for evaluation as a vaccine to prevent amebiasis.

19 esponse and tissue damage seen in intestinal amebiasis.

20 ty is an important defense mechanism against amebiasis.

21 can produce protective immunity to invasive amebiasis.

22 most common extraintestinal complication of amebiasis.

23 ngladeshi infants from cryptosporidiosis and amebiasis.

24 amoeba histolytica is the causative agent of amebiasis, a disease that is a major source of morbidity

25 Entamoeba histolytica causes invasive amebiasis, a major parasitic disease of the developing w

26 is of cryptosporidiosis and the diagnosis of amebiasis and giardiasis, and some new leads on the trea

27 cient for vaccine protection from intestinal amebiasis and reveal an important role for IFN-gamma, ev

28 ling is important in mucosal defense against amebiasis and that polymorphisms in the leptin receptor

29 response in the tissue damage observed with amebiasis and the role of the intestinal epithelial cell

30 rophagocytosis is characteristic of invasive amebiasis, and mutants deficient in erythrocyte ingestio

31 nd in other infections such as Lyme disease, amebiasis, and schistosomiasis.

32 auranofin represents a promising therapy for amebiasis, and the drug has been granted orphan-drug sta

33 amoeba histolytica, the etiological agent of amebiasis, as one of the causes of moderate-to-severe di

34 Leptin signaling protects from amebiasis, but the molecular mechanism is not understood

35 lack of a complete infection animal model of amebiasis by oral-fecal infection.

36 Theses findings indicate that immunity to amebiasis can develop in some children after intestinal

37 The bedside diagnosis of amebiasis could improve patient care.

38 ommon infections caused by enteric protozoa (amebiasis, cryptosporidiosis, and giardiasis), rotavirus

39 This association may explain why amebiasis does not occur in some children who are expose

40 Invasive amebiasis due to Entamoeba histolytica infection is an i

41 histolytica, the etiologic agent of invasive amebiasis, has only recently been recognized to be a dis

42 ce was found of acquired mucosal immunity to amebiasis in Bangladeshi children, offering a guide for

43 tor (Q223R) that increases susceptibility to amebiasis in humans and mice was found to increase susce

44 es with both innate and acquired immunity to amebiasis indicate that CD4+ T cells play a role in prot

45 Amebiasis, infection with the protozoan parasite Entamoe

46 Amebiasis is a major cause of morbidity and mortality wo

47 Resistance to amebiasis is associated with a polymorphism in the lepti

48 s population have shown that protection from amebiasis is associated with mucosal anti-E. histolytica

49 Amebiasis is the fourth leading cause of death and the t

50 duce tropical infectious diseases, including amebiasis, malaria, leishmaniasis, toxoplasmosis, schist

51 specific IgG that does not prevent invasive amebiasis or recurrent infection.

52 demonstrated that sera from acutely infected amebiasis patients recognized and immunoprecipitated the

53 Entamoeba histolytica, the cause of invasive amebiasis, phagocytoses apoptotic host cells during tiss

54 ly developed gnotobiotic model of intestinal amebiasis should enable testing of this hypothesis and p

55 fies the lectin epitopes to be studied in an amebiasis subunit vaccine designed to elicit mucosal imm

56 We designed an amebiasis subunit vaccine that is constructed by using f

57 her supported by colon biopsy of humans with amebiasis that demonstrated suppressed K(+) channel expr

58 nt subunits can protect mice from intestinal amebiasis upon intracecal challenge.

59 , offering a guide for the development of an amebiasis vaccine.

60 influence myelopoiesis and susceptibility to amebiasis via epigenetic mechanisms.

61 Susceptibility to amebiasis was assessed, and cecal tissues were analyzed

62 al IL-1beta and IL-8 in response to invasive amebiasis was confirmed by enzyme-linked immunosorbent a

63 f neutrophils in tissue damage observed with amebiasis was studied by depleting neutrophils from SCID

64 the protozoan parasite that causes invasive amebiasis, which is endemic to many developing countries